RAPORT DE AUTOEVALUARE perioada: 1 iulie 2005-30 iunie 2010 1. Datele de autentificare ale unităţii de cercetare-dezvoltare 1.1. Denumirea: INSTITUTUL ONCOLOGIC Prof. Dr. I. CHIRICUTA CLUJ-NAPOCA 1.2. Statutul Juridic 1 ): Unitate Sanitara Institut cu Personalitate Juridica - INSTITUTUL ONCOLOGIC Prof. Dr. I. CHIRICUTA CLUJ-NAPOCA 1.3. Actul de infiintare 2 ): Hotărârea de Guvern Nr. 144/2010 1.4. Numărul de înregistrare in Registrul potenţialilor contractori:1428 1.5. Manager : Conf.Dr. Alexandru Irimie 1.6. Adresa: Republicii 34-36, CLUJ NAPOCA 1.7. Telefon, fax, pagina web, e-mail: 0264-598361; 0264-598365; www.iocn.ro, office@iocn.ro 2. Domeniul de specialitate 2.1. Conform clasificării UNESCO 3 ): 3289 2.2. Conform clasificării CAEN: principal 8610 ; secundar 7310 3. Starea unităţii de cercetare-dezvoltare 3.1. Misiunea unităţii de cercetare-dezvoltare, direcţiile de cercetare, dezvoltare, inovare: (maximum 1.000 de caractere): Viziunea noastră este de a contribui substanţial la ameliorarea tratamentelor oncologice prin integrarea activităţii de cercetare fundamentală aplicativă cu cercetarea şi practica clinică. Misiunea Departamentului de cercetare ştiinţifică este de a planifica, proiecta şi pune în practică strategii menite a asigura un nivel ridicat de performanţă al cercetării ştiinţifice în Institutul Oncologic Prof. Dr. Ion Chiricuţă, în context naţional şi internaţional. Direcţiile principale de acţiune ale Departamentului de cercetare ştiinţifică sunt: a. promovarea excelenţei în cercetare; 1
b. modernizarea şi eficientizarea bazei materiale a cercetării ştiinţifice din Institut c. orientarea cercetării din Institutul Oncologic Prof. Dr. Ion Chiricuţă spre nevoile pe termen mediu şi lung ale specialităţilor medicale implicate în tratamentul cancerului şi pe un plan mai general ale societăţii noastre. d. realizarea unui management eficient şi eficace al activităţii de cercetare ştiinţifică e. întărirea dimensiunii cooperării internaţionale f. crearea unui climat de încredere şi cooperare ştiinţifică între cercetătorii IOCN cadrele didactice ale UMF Cluj care lucrează cu integrare clinică în Institut, ceilalţi specialişti, bazat pe transparenţă decizională g. dimensiunea educaţională: atragerea de cercetători tineri şi formarea acestora pentru a deveni competitivi pe plan naţional şi internaţional h. evaluarea periodică a rezultatelor cercetării ştiinţifice şi a centrelor de cercetare ştiinţifică existente în Institut. Aceste direcţii de acţiune au în vedere creşterea relevanţei cercetării ştiinţifice în Institutul Oncologic Prof. Dr. Ion Chiricuţă, promovarea acesteia pe plan naţional şi internaţional şi integrarea cercetării ştiinţifice în aria cercetării europene. 3.2. Modul de valorificare a rezultatelor de cercetare, dezvoltare, inovare si gradul de recunoaştere a acestora (maximum 1.000 de caractere): Cercetarea în oncologie are un pronunţat caracter multidisciplinar. Valorificarea rezultatelor cercetării de laborator este posibilă prin translaţia acestora în practica clinică cu scopul de a individualiza tratamentele şi de a introduce metode terapeutice noi. Deasemenea cercetarea clinică (studiile clinice) este cea care validează pe plan practic valoarea diferitelor tratamente. Institutul este partener la numeroase studii clinice, iar unele dintre aceste sunt iniţiate chiar în Institut. Ne propunem creşterea progresivă a numărului de pacienţi care sunt trataţi în studii clinice ca un indicator al performanţei sectorului de cercetare şi creşterea ponderii cunoştinţelor care să facă obiectul transferului din laborator la patul bolnavului. 2
Recunoaşterea acestor rezultate trebuie concretizată prin creşterea numărului de publicaţii în reviste cotate pe plan naţional şi mai ales internaţional. 3.3. Situaţia financiara - datorii la bugetul de stat: NU SUNT 4. Criterii primare de performanta punctaj 4.1. Lucrări ştiinţifice/tehnice publicate in reviste de specialitate cotate ISI 4 ) 4.1.1. Număr de lucrări ştiinţifice 84 x 30 =2520 4.1.2. Punctaj cumulat ISI 5 ) 324.714 x 5= 1623.57 4.1.3. Număr de citări in reviste de specialitate cotate ISI 6 ) 4031x 5 = 20155 (Lista lucrărilor si citărilor, grupate pe ani, se ataşează ca anexa nr. 4.1) Total punctaj cap. 4.1: 24298.57 4.2. Brevete de inventie 7 ) 4.2.1. Număr de brevete x 30 4.2.2. Număr de citări de brevete in sistemul ISI x 5 (Lista brevetelor si citărilor, grupate pe ani, se ataşează ca anexa nr. 4.2) Total punctaj cap. 4.2: 0 4.3. Produse si tehnologii rezultate din activitati de cercetare, bazate pe brevete, omologări sau inovaţii proprii. Studii prospective si tehnologice si servicii rezultate din activitatea de cercetare-dezvoltare, comandate de beneficiar (Se indica contractul si firma care utilizează produsul, serviciul si tehnologia). 4.3.1. Număr de produse, tehnologii, studii, servicii 11 x 20 = 220 (Lista produselor, serviciilor si tehnologiilor, grupate pe ani, se ataşează ca anexa nr. 4.3) Total punctaj cap. 4.3: 220 Total punctaj cap. 4: 24518.57 3
5. Criterii secundare de performanta 5.1. Lucrări ştiinţifice (tehnice) publicate in reviste de specialitate 8 ) fără cotaţie ISI 5.1.1. Număr de lucrări 41 x 5 = 205 (Lista lucrărilor grupate pe ani se ataşează ca anexa nr. 5.1) Total punctaj cap. 5.1: 5.2. Lucrări ştiinţifice prezentate la conferinţe internaţionale cu comitet de program 5.2.1. Număr de comunicări prezentate 159 x 5 =795 (Lista comunicărilor grupate pe ani se ataşează ca anexa nr. 5.2) Total punctaj cap. 5.2: 5.3. Modele fizice, modele experimentale, modele funcţionale, prototipuri,normative, proceduri, metodologii, reglementari si planuri tehnice noi sau perfecţionate, realizate in cadrul programelor naţionale sau comandate de beneficiar 5.3.1. Număr de modele, normative, proceduri etc.: 1 x 5 = 5 (Lista modelelor, normativelor etc., grupate pe ani, se ataşează ca anexa nr. 5.3) Total punctaj cap. 5.3: 5 Total punctaj cap. 5: 205+795+5=1005 6. Prestigiul profesional 6.1. Membri (incluzând statutul de recenzor) in colectivele de redacţie ale unor reviste (cotate ISI sau incluse in baze de date internaţionale) sau in colective editoriale ale unor edituri internaţionale recunoscute Număr de prezente in perioada pentru care se face evaluarea: 5 x 20=100 Nr. crt. Nume Titlul revistei/editurii 6.2. Membri in colectivele de redacţie ale revistelor recunoscute naţional (din categoria B in clasificarea CNCSIS) Număr de prezente: 1 x 10=10 4
Nr. crt. Nume Titlul revistei/editurii 6.3. Premii internaţionale obţinute printr-un proces de selecţie Anexa 6.3 Număr de premii: 7 x 20 = 140 Nr. crt. Nume Premiul Anul 6.4. Premii naţionale ale Academiei Romane Număr de premii: x 20 Nr. crt. Nume Premiul Anul 6.5. Conducători de doctorat, membri ai unităţii de cercetare Număr de conducători de doctorat: x 10 Nr. crt. Nume 6.6. Număr de doctori in ştiinţa, membri ai unităţii de cercetare Număr de doctori in ştiinţa: 10 x 10 = 100 Total punctaj cap. 6:100+10+140+100=350 Total punctaj cap. 4+5+6: 24518.57+1005+350=25873.57 7. Venituri realizate prin contracte de cercetare in domeniul pentru care se face evaluarea (in perioada pentru care se face evaluarea): 7.1. Numărul si valoarea contractelor de cercetare internaţionale finanţate din fonduri publice 9 ): 7.2. Numărul si valoarea contractelor de cercetare internaţionale finanţate din fonduri private: 7.3. Numărul si valoarea contractelor de cercetare naţionale finanţate din fonduri publice 10 ): an Nr. proiecte tip program 2005 8 1 - grant 4 CEEX VIASAN 3 -PNCD I VIASAN Valoare in RON pe an 2.000 167.500 229.960 Valoare Valoare totala RON totala in pe an EUR pe an 399.460 114.131,43 5
2006 27 2 granturi 69.000 1.523.708 435.345,14 22 CEEX VIASAN, CNMP 3 PNCD I VIASAN 1265.828 188.880 2007 34 1 PNCD II CNCSIS 99.000 2.642.957 755.130,57 23 CEEX 3 PNCD I VIASAN 7 PNCD II Pr 4 2103.892 136.880 303.185 2008 35 1 PNCD II CNCSIS 17 CEEX 374.000 3.099.308 4.722.635 1.185.043,4 1 3 PNCD I VIASAN 14 PNCD II PR IV 75.000 1.174.327 2009 16 2 PNCD II CNCSIS 288.221 990.027 234.148,57 14 PNCD II PR IV 701.806 TOTAL 10.278.787,0 0 2.723.799,1 2 7.4. Numărul si valoarea contractelor de cercetare naţionale finanţate din fonduri private: 7.5. Alte surse: 7 bis. Venituri realizate din activităţi economice (servicii, microproducţie): 8. Resursa umana de cercetare 8.1. Total personal de cercetare care realizează venituri din activitatea de cercetaredezvoltare/din care doctori in ştiinţa: 8.1.1. Cercetători ştiinţifici gradul 1 (profesori)/din care doctori in ştiinţa: 3/3 8.1.2. Cercetători ştiinţifici gradul 2 (conferenţiari)/din care doctori in ştiinţa: 6/6 8.1.3. Cercetători ştiinţifici gradul 3 (lectori)/din care doctori in ştiinţa: 1/1 8.1.4. Cercetători ştiinţifici/din care doctori in ştiinţa: 3/0 8.1.5. Asistenţi de cercetare: 4/1 8.1.6. Total personal auxiliar de cercetare angajat: 18 6
8.2. Date privind perfecţionarea resursei umane 8.2.1. Număr de doctoranzi si masteranzi care lucrează in unitatea de cercetare-dezvoltare la data completării formularului: 8 8.2.2. Număr de teze de doctorat realizate in unitatea de cercetare-dezvoltare in perioada pentru care se face evaluarea:13 9. Infrastructura de cercetare-dezvoltare 9.1. Laboratoare de cercetare-dezvoltare: ORGANIGRAMA IN ANEXA 9.2. Lista echipamentelor performante achiziţionate in ultimii 10 ani: Nr. crt. Echipamentul Anul fabricaţiei Valoarea Sursa de finanţare a investiţiei Nr. crt. Echipament Anul achiziţionării Valoarea Sursa de finanţare a investiţiei 1 Sistem HPLC 2001 155.905,72 Grant Banca Mondiala UMF (custodie IOCN) 2 Secventiator automat 2001 140.335,1 Grant Banca Mondiala UMF (custodie IOCN) 3 Centrifuga de laborator 2001 10.153,83 Grant Banca Mondiala UMF (custodie IOCN) 4 Procesor Vysis VP2000 2001 69.277 Grant Banca Mondiala UMF (custodie IOCN) 5 Analizator de imagini pt electr. 2001 45.116,23 Grant Banca Mondiala UMF 7
(custodie IOCN) 6 Spectrofotometru UV cu db 2001 40.497,66 Grant Banca Mondiala UMF (custodie IOCN) 7 Sistem imobilizare 2001 3.937,59 Grant Banca Mondiala UMF (custodie IOCN) 8 Celula de transfer pt statting 2001 18.839,24 Grant Banca UMF (custodie IOCN)Mondiala 9 Instalatie de Electroforeza medicala 2001 43.439,01 Grant Banca Mondiala UMF (custodie IOCN) 10 Sistem de analiza automata 2001 203.062,02 Grant Banca Mondiala UMF (custodie IOCN) 11 Centrifuga universala cu acces 2001 48.563,54 Grant Banca Mondiala UMF (custodie IOCN) 12 Hota in flux laminar 2001 16.691,33 Grant Banca Mondiala UMF (custodie IOCN) 13 Sistem de analiza a imaginii 2002 141.937,72 Grant Banca Mondiala UMF (custodie IOCN) 14 Sistem Electroforeza 2002 71.232,75 Grant Banca Mondiala UMF (custodie IOCN) 15 Sistem pt microfotografiere 2002 76.893,60 Grant Banca 8
Mondiala UMF (custodie IOCN) 16 Microscop E 1000 Nikon 2002 134.563,8 Grant Banca Mondiala UMF (custodie IOCN) 17 Hota HH 1-2 Plus 2002 16.843,01 Grant Banca Mondiala UMF (custodie IOCN) 18 Incubator 2002 14.393,87 Grant Banca Mondiala UMF (custodie IOCN) 19 Cititor Elisa cu spalator 2002 23.748,81 Grant Banca Mondiala UMF (custodie IOCN) 20 Analizor de citometrie cu acces... 2003 184.725,41 Chelt generale universitare UMF (custodie IOCN) 21 Masa chirurgicala cu acesorii 2005 64.092,21 Cercetare MEC 22 Trusa chirurgie laparoscopica 2005 150.854,16 Cercetare MEC 23 Monitor pacient MEC 1000 2005 11.109 Cercetare MEC 24 Monitor pacient MEC 1000 2005 11.109 Cercetare MEC 25 Monitor pacient MEC 1000 2005 11.109 Cercetare MEC 26 Sistem PCR 96 WELL 2006 21.658 Cercetare MEC 27 Hota bacteriologica Lamil 2006 23.389,45 Cercetare MEC Plus 16 28 Upgrade sistem de stocare si 2006 27.000 Cercetare MEC transmisie imagini 29 Incubator cu CO2 2006 32.487 Cercetare MEC 30 Incubator cu CO2 2006 23.431,5 Cercetare MEC 9
31 Spectrofotometru UV VIS 2006 27.908,48 Cercetare MEC (sistem analiza nanodrop) 32 Centrifuga Universal 320R cu 2006 23.211,79 Cercetare MEC racire 33 Hota bacteriologica lamil plus 2006 21.967,40 Cercetare MEC 10 34 Omogenizator (procesor ) cu 2006 12.560,10 Cercetare MEC ultrasunete 35 Aparat fabricat fulgi de 2007 11426 CNCSIS gheata 36 Criocauter cu acesorii 2007 22.201,83 Cercetare MEC 37 Electrocauter MBC 600 2007 21.082,27 Cercetare MEC 38 Electrocauter seria 78377 2007 20.675,31 Cercetare MEC 39 Statie includere la parafina 2007 31.502,16 Cercetare MEC 40 Aparat de produs gheata 2007 14.489,62 Cercetare MEC Ziegra 41 Aparat maruntit probe 2007 8.658,44 Cercetare MEC biologice seria 30208 42 Ultracongelator vertical 440 l, 2007 30.675,23 Cercetare MEC -86 0 C 43 Vas Dewar azot lichid - rack 2007 16.842,37 Cercetare MEC 44 Vas Dewar azot lichid 2007 9.991,49 Cercetare MEC 45 Traductor endocavitar EC123 2007 27.728,19 Cercetare MEC 46 Balanta analitica cu 5 2007 10.549,35 Cercetare MEC zecimale si incinta cantarire 47 Hota cu flux laminar Lamil 2007 22.530,98 Cercetare MEC Plus 48 Aparat foto digital Olympus E330 2007 15.670 Cercetare MEC 10
49 Dulap rack black 19 2007 17.600 Cercetare MEC 50 Microscop inversat config 2007 170.635,29 Cercetare MEC completa 51 Separator de celule 2007 8.093,74 Cercetare MEC 52 Vas Dewar 10 l 2007 3.690,73 Cercetare MEC 53 Microtom RM 2125 2007 21.227,42 Cercetare MEC 54 Microtom RM 2125 2007 21.227,42 Cercetare MEC 55 Statie de lucru GROSSLAB SR 2007 66.000 Cercetare MEC 56 Centrifuga cu racire 2007 10.438,68 Cercetare MEC MIKRO200R 57 Electroporator 2007 18.772,25 Cercetare MEC Microscop pt.analize Cercetare MEC 14.385,67 58 histologice 2007 Sistem siguranta Back-up Cercetare MEC 5.287,17 59 CO2 2007 60 Autostainer 2007 162.292,53 Cercetare MEC Sursa de lumina pt.lupe Cercetare MEC 61 operatorii 2007 6.506,85 62 Hota de culturi clasa a II-a 2007 17.600,85 Cercetare MEC 63 Etuva de laborator - pupinel 2007 3.803,24 Cercetare MEC 64 Camera foto NIKON 2007 6.479,55 Cercetare MEC 65 Lupe operatorii 2007 7.282,80 Cercetare MEC 66 Infusomat FMS 2007 5.569,20 Cercetare MEC 67 Centrifuga cu racire 2007 14.137,20 Cercetare MEC 68 Placa sofanta 2007 2.817,09 Cercetare MEC 69 Balanta analitica cu 5 zec. 2007 3.516,39 Cercetare MEC 70 Hota laminara 2007 12.643,94 Cercetare MEC 71 Dozimetru personal digital 2007 6.479,55 Cercetare MEC 11
72 Microscop inversat motorizat 2007 170.635,29 Cercetare MEC 73 Cititor de microplaci 2008 135.656,43 Cercetare MEC Geldoc XR System (Sistem de Cercetare MEC 74 analiza western blott) 2008 45.993,50 Sistem de electroforeza si Cercetare MEC 75 Western Blotting 2008 16.303,00 76 Placa sofanta 2008 6.892,88 Cercetare MEC Disp.pt.tehnica Tisuue Cercetare MEC 8.496,60 77 microassay 2008 78 Detector de ozon 2008 39.680,55 Cercetare MEC 79 Procesor tesuturi 2008 124.937,92 Cercetare MEC 80 Incubator de culturi celulare 2008 17.635,80 Cercetare MEC Instalatie de purificare a Cercetare MEC 81 aerului 2008 45.941,14 82 Hota cu flux laminar cls. II 2008 44.510,28 Cercetare MEC Placa de baza pt.fix.pacient + Cercetare MEC 21.935,27 83 accesorii 2008 84 LAMPA BACTERICIDA 60 PL 2008 3.000,00 Cercetare MEC 85 Centrifuga cu racire 2008 37.213,68 Cercetare MEC 86 Procesor de tesuturi 2008 62786.32 Cercetare MEC 87 Hota de culturi cls.ii 2008 7.259,00 Cercetare MEC 88 Lightcycler 2008 185.640,00 Cercetare MEC 89 Lampa scialitica cu satelit 2008 41.888,00 Cercetare MEC Instalatie de purificare a Cercetare MEC 90 aerului pentru indepartarea speciilor de ozon active 2008 91.882,28 91 Upgrade Microscop Zeiss Axio Observer 2008 99.305,50 Cercetare MEC 12
92 Pistol de prelevare biopsii 2008 9.282,00 Cercetare MEC 93 Ecograf Acuson X 300 2008 104.779,50 Cercetare MEC Sistem de upgradare Cercetare MEC 94 centrifuga Universal 32 R 2008 3.857,98 95 Analozor lightcycler 2008 185.640,00 Cercetare MEC 96 UV/Metru 2009 7.199,50 Cercetare MEC Lampa cercetare cu Cercetare MEC 97 ultraviolete 2009 6.985,30 98 Tije politron 2009 46.652,76 CNCSIS 99 UV/Metru 2009 7.199,50 Cercetare MEC Lampa cercetare cu Cercetare MEC 100 ultraviolete 2009 6.985,30 Locator 4110 litri cu sistem Cercetare MEC 101 de role portabile 2009 31.319,26 102 Platforma microarray 2007 145.000 Cercetare MEC 1 ) Se mentioneaza forma de organizare si persoana juridica: daca unitatea de cercetaredezvoltare nu are personalitate juridica, se mentioneaza denumirea institutiei cu personalitate juridica care o reprezinta (de exemplu, Centrul de... din cadrul Universitatii...). 2 ) Se mentioneaza titlul actului, data emiterii, organul emitent si, dupa caz, modificarile ulterioare 3 ) Domeniile de clasificare UNESCO pot fi accesate la www.mct.ro/ancs. 4 ) Indexate de Thomson Scientific [fost Institute for Scientific Information (ISI) in Science Citation Index Expanded, Social Sciences Citation Index sau Arts & Humanities Citation Index]. 5 ) Punctajul ISI se obtine prin insumarea factorilor de impact ai publicatiilor respective. Factorii de impact pot fi accesati la www.cimec.org.ar. 6 ) Sunt excluse autocitarile. 13
7 ) Se specifica daca brevetul este national/international (USPTO, EPO, JPO) si numarul brevetului. 8 ) In cazul revistelor romanesti, sunt luate in considerare cele cotate CNCSIS, categoria B (vezi www.cncsis.ro). 9 ) Valori defalcate pe ani si valoarea totala in euro. 10 ) Datele vor fi prezentate pe tipuri de programe (PNCDI, CEEX, granturi etc.); valorile contractelor vor fi defalcate pe ani. Reprezentant legal Institutul Oncologic Prof Dr I.Chiricuta Manager Conf.Dr.Alexandru Irimie Director cercetare - dezvoltare Sef lucrari. Dr. Ioana Neagoe 14
ANEXA 4.1 Lucrari stiintifice/tehnice publicate in reviste de specialitate cotate ISI 4 ) 84X 30 = 2520 ; Punctaj cumulat ISI 324.714 x 5= 1623.57 ; Citari 4031 X 5 = 20.155 Total= 24298.57 2005 1. I.D. Postescu, C. Tatomir, G.Chereches, I.Brie, G.Damian, D.Petrisor, A.M.Hosu, N.Pop: Spectroscopic characterisation of grape extracts with potential role in tumor growth inhibition, J. Optoel. Adv. Materials (JOAM), 9, 564-567, 2007 (ISI-2005, impact factor 1.138) citari 6 2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.PMID: 16014882 Factor de impact 2005-44,016 3. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005 Oct;10(9):665-85. Review.PMID: 16249346 Factor de impact 2005 3,962 4. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: results from a randomised, placebo-controlled, multicentre study 15
(Iressa Survival Evaluation in Lung Cancer). Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37.PMID: 16257339 Factor de impact 23,4 2006 5. - R.Cosnarovici, Şt. Neamţu, E.Mihuţ, D.Cernea, N.Todor, Luciana Neamţiu, The benefit of high dose methotrexate terapy in childhood, Pediatric Blood & Cancer, 47,4, pp.443-444 Factor de impact 1,882 6. Veronique Winnepenninckx, Vladimir Lazar, Stefan Micheils, Philippe Dessen, Marguerite Stas, Soledad R. Alonso, Marie-Franoise Avril, Pablo L. Ortiz Romero, Thomas Robert, Ovidiu Balacescu, Alexander M.M. Eggremont, Gilbert Lenoir, Alain Sarasin, Thomas Tursz, Joost J. van den Oord, Alain Spatz. On behalf of the Melanoma Group of the European Organization for Research and Treatment of Cancer. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst, 2006 apr 5, 98 (7): 472-82.factor de impact 15,271 nr de citari -106 in sistem Google Scholar 7. Dorhoi, V. Dobrean, M. Zahan, P. Virag. Modulatory effects of several herbal extracts on avian peripheral blood cell immune responses, Phytotherapy Research, factor de impact 0, 508, 2006, 20(5): 352-358. John Wiley & Sons 8. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-smallcell lung cancer. J Clin Oncol. 2006 Nov 1;24(31):5034-42.PMID: 17075123 Factor de impact 1.376 16
9. Eniu A, Carlson RW, Aziz Z, Bines J, Hortobágyi GN, Bese NS, Love RR, Vikram B, Kurkure A, Anderson BO; Global Summit Treatment and Allocation of Resources Panel. Breast cancer in limited-resource countries: treatment and allocation of resources Breast J. 2006 Jan-Feb;12 Suppl 1:S38-53.PMID: 16430398 Factor de impact 1,61 10. Benjamin O. Anderson, MD*, Roman Shyyan, MD, Alexandru Eniu, MD, Robert A. Smith, PhD, Cheng-Har Yip, MD, Nuran Senel Bese, MD #, Louis W. C. Chow, MD ^, Shahla Masood, MD, Scott D. Ramsey, MD, PhD, and Robert W. Carlson, MD** *University of Washington, Seattle, Washington; Lviv Cancer Center, Lviv, Ukraine; Cancer Institute I. Chiricuta, Cluj-Napoca, Romania; American Cancer Society, Atlanta, Georgia; University of Malaya Medical Center, Kuala Lumpur, Malaysia; # Cerrahpasa Medical School, Istanbul, Turkey; ^ University of Hong Kong Medical Center, Pokfulam, Hong Kong; University of Florida, Jacksonville, Florida; Fred Hutchinson Cancer Research Center, Seattle, Washington; and **Stanford University, Stanford, California Breast Cancer in Limited-Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines The Breast Journal 2006 Volume 12 Issue s1, Pages S3 - S15 Published Online: 16 Jan 2006 Factor de impact 1,61 11. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006 May;52(2):155-63. Epub 2006 Mar 29.PMID: 16569462 Factor de impact 3.554 17
12. Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia. Medical Hypotheses, ISSN 0306-9877, 66:352-354, 2006 idexat ISI IF=1.393 2007 13. Daria Cosaceanu, Mia Carapancea, Oana Alexandru, Raluca Budiu, Hanna- Stianmartinsson, Maria Starborg, Maria Vrabete, Lena Kanter, Rolf Lewensohn, Anica Dricu. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors; 2007, 25 (1): 1-8. factor de impact 3,95 14. D Cosaceanu, RA Budiu, M Carapaceanu, J Castro, R Lewensohn, A Dricu. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku- DNA binding modulating Ku86 expression via p38 kinase-dependent mechanism. Oncogene, 2007. 26, 2423-2434 factor de impact- 6,582 15. Carapancea M, Cosaceanu D, Budiu R, Kwiecinska A, Tataranu L, Ciubotaru V, Alexandru O, Banita M, Pisoschi C, Backlund ML, Lewensohn R, Dricu A. Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells. Neurooncol. 2007 Dec;85(3):245-54. Epub 2007 Jun 14 factor de impact 1,84 16. Radulescu D, Pripon S, Ciuleanu TE, Radulescu LI. Malignant primary pulmonary tumor with hemangiopericytoma-like features: conventional hemangiopericytoma versus solitary fibrous tumor. Clin Lung Cancer. 2007 Sep;8(8):504-8.PMID: 17922977 Factor de impact - 2,39 18
17. Radulescu D, Pripon S, Parv A, Duncea C, Ciuleanu TE. Altered left ventricular diastolic performance in oncologic patients treated with epirubicin.congest Heart Fail. 2007 Jul-Aug;13(4):215-20.PMID: 17673874 Factor de impact 2007 3,6 18. Grigorescu A, Ciuleanu T, Firoiu E, Muresan DR, Teodorescu G, Basson BR. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung Cancer. 2007 Aug;57(2):168-74. Epub 2007 Apr 30.PMID: 17467848 Factor de impact 2007 3,455 19. I.D. Postescu, C. Tatomir, G. Cherecheş, I. Brie, G. Damian, D. Petrişor, A-M Hosu, V. Miclăuş, A. Pop: Spectroscopic characterization of some grape extracts with potential role in tumor growth inhibition, Journal of Optoelectronics and Advanced Materials, 2007, 9(3), 564-567, Factor de impact 0.577. 2008 20. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.PMID: 18520802 [PubMed - indexed for MEDLINE]Related citations Factor de impact 2008 4,547 21. Smith RE Jr, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008 19
Mar 1;26(7):1040-50. Epub 2008 Jan 28.PMID: 18227526 Factor de impact 2006-13.598 22. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, Masetti R, Anderson BO; Breast Health Global Initiative Treatment Panel. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer. 2008 Oct 15;113(8 Suppl):2269-81.PMID: 18837019 Factor de impact 5,418 23. El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi GN; Breast Health Global Initiative Systemic Therapy Focus Group. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middleincome countries. Cancer. 2008 Oct 15;113(8 Suppl):2315-24.PMID: 18837023 Factor de impact 5,418 24. Masood S, Vass L, Ibarra JA Jr, Ljung BM, Stalsberg H, Eniu A, Carlson RW, Anderson BO; Breast Health Global Initiative Pathology Focus Group. Breast pathology guideline implementation in low- and middle-income countries. Cancer. 2008 Oct 15;113(8 Suppl):2297-304.PMID: 18837021 Factor de impact 5,418 25. Bines J, Eniu A. Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective. Cancer. 2008 Oct 15;113(8 Suppl):2353-8. Review.PMID: 18837028 Factor de impact 5,418 26. Dima D, Trifa AP, Cucuianu A, Popp RA, Patiu M, Petrov L. Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR. Rom Rev Lab Med. 2008, 13,4:17-20 indexat ISI - IF=0 20
27. Patiu M., Laszlo G., Cucuianu A.: Feritins in iron metabolism investigation. Revista Romana de Medicina de Laborator.vol 11 nr 2 iunie 2008 pag 53-55 indexat ISI IF = 0 28. S.Suciu, I.D. Postescu, A. Mureşan, P. Virág, D. Daicoviciu, E. Fischer-Fodor. In vitro and in vivo Studies on the Modulatory Effects of a Grape (Vitis vinifera) Seed Extract, J. Clin. Biochem. Nutr., 2008, Suppl. 43, 493-96, i.f. 0.312. 29. E.Fischer-Fodor, N. Moldovan, P. Virág, O. Soriţău, I. Brie, P. Lonnecke, E. Hey- Hawkins, L. Silaghi Dumitrescu: The CellScan Technology for In Vitro Studies on Novel Platinum Complexes with Organoarsenic Ligands, Dalton Transactions, 2008, 6393-6400, i.f. 3.58. 30. T.Dicu, I. Brie, P. Virág, E. Fischer, M. Perde, V. Foriş, V. Cernea, C. Cosma. Genotoxic effects of 60 Co γ-rays on Chinese hamster ovary (CHO) cells, Nukleonika, 2008, 53 (4), 161-165, i.f. 0.267. 31. A.Filip, S. Clichici, A. Mureşan, D. Daicoviciu, C. Tatomir, C. Login, S. Dreve, C. Gherman: Effects of PDT with 5-aminolevulinic acid and chitosan on Walker Carcinosarcoma. Exp. Oncol., 2008, 30, 3, 212-219, i.f. 0.115. 2009 32. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung 21
cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct 24;374(9699):1432-40. Epub 2009 Sep 18.PMID: 19767093 Factor de impact 30,758 33. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009 Oct 1;27(28):4787-92. Epub 2009 Aug 31.PMID: 19720897Factor de impact 13.598 34. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or nonsmall cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol. 2009 Jun;4(6):736-40.PMID: 19404210 Factor de impact 4,547 35. Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009 May;10(5):467-74. Epub 2009 Apr 20.PMID: 19386548 Factor de impact 10.119 36. Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, Tidmarsh GT. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J 22
Cancer. 2009 Jun;45(9):1589-96. Epub 2009 Jan 31.PMID: 19188061 Factor de impact 4.167 37. O Tudoran. I Berindan Neagoe, O Balacescu, E Dronca, C. Burz, L Balacescu, I Nedelea, Al. Irimie, O. Popescu, Al Irimie, V. Cristea. Evaluation of tumor angiogenesis through VEGF modulkation in ovarian cancer in vitro using RNA interference. Romanian Biotechnological Letters, 2009 vol 14, no.4, 4560-4566. ISI factor impact 0.152 38. Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, Vlase L, Chintoanu M, Balacescu L, Leucuta SE, Irimie A, Cristea V. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. J Gastrointestin Liver Dis. 2009 Mar;18(1):39-43. 1 citare in Google Scholar. FI=1.265 39. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: Key molecular signaling pathways and therapy targets. Acta Oncol. 2009 Jun 9:1-11. ISI, Factor de impact (2008): 2.739 nr de citari -8 in sistem Google Scholar. 40. Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV, Edwards RP. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother. 2009 Aug 19. [Epub ahead of print]. ISI, Factor de impact (2009): 3.791 41. Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM. Dis Model Mech. A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-muc1 antibodies and Foxp3+ regulatory T cells. Dis Model Mech. 23
2009 Nov-Dec;2(11-12):593-603. Epub 2009 Oct 19. ISI, Factor de impact (2009): 3.304 42. Nicula FA. Suteu O. Pais R. Neamtiu L. Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009;45:2685-2708. Factor de impact 4,121 43. Ronco G. Balegooijen M. Becker N. Chil A. Fender M. Giubilato P. Kurtinaitis J. Lancucki L. Lynge E. Morais A. O Reilly M. Sparen P. Suteu O. Rebolj M. Veerus P. Primic Zakelj M. Anttila A. Process performance of cervical screenning programmes in Europe. Eur J. Cancer, 2009;45:2659-2670. Factor de impact 4,121 44. Anttila A. Von Karsa L. Aasmaa A. Fender M. Patnick J. Rebolj M. Nicula F. Vass L.Valerianova Z. Voti L. Sauvaget C. Ronco G. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009; 45:2649-2658. Factor de impact 4,121 45. Nicula F. A. Anttila A. Neamtiu L. Primic Zachelj M. Tachezy R. Chill A. Grce M. Kesic V. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. Eur J Cancer 2009; 45: 2679-2684. Factor de impact 4,121 46. Neamţiu L. A Medical Resources Allocation Problem. Results in Mathematics. Birkhauser Verlag Basel/ Swizerland, 53(2009), p. 341-348. Factor de impact 0,513 47. Buzas C, Sparchez Z, Cucuianu A, Manole S, Lupescu I, Acalovschi M. Budd-Chiari syndrome secondary to polycythemia vera. A case report. J Gastrointest Liver Dis, 2009, 18(3):363-6 indexat ISI IF=1.265 24
48. Trifa AP, Popp RA, Cucuianu A, Dima D, Militaru MS, Patiu M, Pop IV. JAK2 p.v617f mutation - tetra-primer PCR and PCR-RFLP comparative semiquantitative approaches for estimation of the mutant allele in myeloproliferative neoplasms. Rom Rev Lab Med. 2009, 14,1:23-36 indexat ISI IF=0 49. P.Virág, I. Brie, I.D. Postescu, M. Perde-Schrepler, E. Fischer-Fodor, O. Soriţău, A. Irimie, V. Cernea. Comparative study of two evaluation methods for the genotoxic effects of environmental heavy metals on normal cells, Toxicol. Ind. Health, 25 (4-5), 2009, 253-8, i.f. 0.700. 50. A. Filip, S. Clichici, D. Daicoviciu, A.Mureşan, I. D. Postescu, M. Perde- Schrepler, D. Olteanu: Photochemoprevention of cutaneous neoplasia through natural products, Exp. Oncol., ISSN 0204-3564, 2009 Mar; 31(1), 9-15, i.f. 0.115. 51. T. Dicu, I. D. Postescu, V. Foriş, I. Brie, E. Fischer-Fodor, M. Moldovan, C. Cosma: The effect of a grape seed extract on radiation-induced DNA damage in human lymphocytes, Amer. Inst. Phys. Conf. Proceed., 2009, 1131, 181-187. 52. M. C. Mihu, D. Rus Ciucă, O. Soriţău, S. Susman, D. Mihu: Isolation and characterization of mezenchymal stem cells from the amniotic membrane, Romanian Journal of Morphology and Embryology, 2009; 50(1):73-77. 53. M. Lukáč, M. Mrva, E. Fischer-Fodor, I. Lacko, M. Bukovský, N. Miklášová, F. Ondriska, F. Devínsky : Synthesis and biological activity of dialkylphosphocholines Elsevier, Bioorganic & Medicinal Chemistry Letters 19, 2009, 6346-6349, i.f. 2.531. 54. N. Miklášová, E. Fischer-Fodor, P. Lonnecke, M. Perde Schrepler, P. Virág, C. Tatomir, V. I. Cernea, E. Hey-Hawkins, L. Silaghi- Dumitrescu: Antiproliferative effect 25
and genotoxicity of novel synthesized palladium complexes with organoarsenic ligands, J. Inorg. Biochem., 2009, 103, 1739-1747, i.f. 3.133. 55. C. Tomuleasa, S. Şuşman, O. Soriţău, V. Foriş, E. Páll, C. Mihu: Primum non nocere. Is stem cell research ready for clinical trials?, Journal of Euroepan Medical Students Association on Medical and Scientific Affairs JEMSA, 2009, 34-38. 56. C. Tomuleasa, V. Foris, O. Soriţău, E. Páll, E. Fischer-Fodor, V. Lung-Illes, I. Brie, P.Virág, M. Perde-Schrepler, I. D. Postescu, G. Cherecheş, O. Bărbos, C. Tatomir. Effects of 60Co gamma-rays on human osteoprogenitor cells.rom J Morphol Embryol 2009; 50(3):349-55. 57. O. Lucaciu, M. Băciuţ, G. Băciuţ, D. Gheban, S. Bran, M. Hedeşiu, C. Nicola, O. Soriţău, D. Gui: Bone Regeneration in Craniofacial Reconstruction with Particulate Grafts Obtained Through Tissue Engineering. Particulate Science and Technology An International Journal, 2009 ; 27, 6, 497 518, ISSN- 0272-6351, i.f. 0.417. 58. A. Mureşan, Ş. Suciu, S. Ghibu, D. Daicoviciu, I. D. Postescu, I. Login: Antioxidant effects of polyphenols in experimental hypobaric hypoxia, Bull. USAMV, 2009, 66(1), 160-164 (revistă ISI din 2009). ISSN-1454-2382. 59. Seicean A, Popa D, Mocan T, Cristea V, Neagoe I. Th1 and Th2 profiles in patients with pancreatic cancer compared with chronic pancreatitis. Pancreas. 2009 Jul;38(5):594-5.Factor de impact 2,733 60. I. Berindan Neagoe, O. Balacescu, C. Burz, C. Braicu, L. Balacescu, O. Tudoran, T.Kaucsar, V.Cristea, A. Irimie. p53 gene therapy using RNA interference. Journal of B.U.O.N.14,SEPT 2009, S 51-S 59 Factor de Impact 0.783 26
2010-61. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-smallcell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. Epub 2010 May 20.PMID: 20493771 Factor de impact 10.119 62. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010 Apr 27. [Epub ahead of print]pmid: 20473913 Factor de impact 4.693 63. Steger GG, Abrahámová J, Bacanu F, Brincat S, Brize A, Cesas A, Cufer T, Dank M, Duchnowska R, Eniu A, Jassem J, Kahán Z, Matos E, Padrik P, Plāte S, Pokker H, Purkalne G, Timcheva C, Tzekova V, Vyzula R, Zielinski CC. Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr. 2010 Jun;122(11-12):368-79. Epub 2010 Jun 15.PMID: 20549373 Factor de impact 0.804 64. Cornelia Braicu, Dumitrita Rugina, Veronica Sanda Chedea, Oana Tudoran, Ovidiu Balacescu, Ioana Neagoe And Carmen Socaciu, Protective action of different natural flavan-3-ols against aflatoxin B1-related cytotoxicity, Journal of Food Biochemistry, Volume 34 Issue 3, Pages 595 610, Published Online: 3 Mar 2010; ISI, Factor de impact (2009)=0.779; nr de citari -1 in sistem Google Scholar. 27
65. Achimaş-Cadariu P, Irimie A, Achimaş-Cadariu L, Neagoe I, Buiga R. Chirurgia (Bucur). 2009 May-Jun;104(3):287-93. ISI 66. Cornelia Braicu, Ioana Berindan-Neagoe, Veronica Sanda Chedea, Loredana Balacescu, Ioana Brie, Olga Soritau, Carmen Socaciu, Alexandru Irimie. Individual and combined cytotoxic effects of the major four aflatoxins in different in vitro stabilized systems, Journal of Food Biochemistry Published Online: Mar 3 2010 4:34AM, DOI: 10.1111/j.1745-4514.2010.00350.x ISI, Factor de impact (2009)=0.77. 67. Veronica Sanda Chedea, Cornelia Braicu, Carmen Socaciu, Antioxidant/prooxidant activity of a polyphenolic grape seed extract, Food Chemistry, Volume 121, Issue 1, Published Online: 1 July 2010, Pages 132-139, doi:10.1016/j.foodchem.2009.12.020 ISI Factor de impact (2009)= 3.146 68. Rantakari P, Nikkilä J, Jokela H, Ola R, Pylkäs K Lagerbohm H, Sainio K, Poutanen M, Winqvist R. Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice. Hum Mol Genet. 2010 Aug 1;19(15):3021-9. Epub 2010 May 18. ISI, Factor de impact (2010):7.386 69. Jokela H, Rantakari P, Lamminen T, Strauss L, Ola R, Mutka AL, Gylling H, Miettinen T, Pakarinen P, Sainio K, Poutanen M. Hydroxysteroid (17beta) dehydrogenase 7 activity is essential for fetal de novo cholesterol synthesis and for neuroectodermal survival and cardiovascular differentiation in early mouse embryos. Endocrinology. 2010 Apr;151(4):1884-92. Epub 2010 Feb 25. ISI, Factor de impact (2009):5.257 70. Jääskeläinen M, Prunskaite-Hyyryläinen R, Naillat F, Parviainen H, Anttonen M, Heikinheimo M, Liakka A, Ola R, Vainio S, Vaskivuo TE, Tapanainen JS. Mol Cell 28
Endocrinol. 2010 Apr 12;317(1-2):106-11. Epub 2009 Dec 3. WNT4 is expressed in human fetal and adult ovaries and its signaling contributes to ovarian cell survival. Mol Cell Endocrinol. 2010 Apr 12;317(1-2):106-11. Epub 2009 Dec 3. ISI, Factor de impact (2009): 3.503 71. Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru S, Dima D, Pop IV, Popp RA.The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann. Hematol 2010 Apr 27 (epub ahead of print) indexat ISI IF=2.919 72. Trifa AP, Cucuianu A, Popp RA. Development of a reliable PCR-RFLP assay for investigation of the JAK2 rs10974944 SNP, which might predispose to the acquisition of somatic mutation JAK2(V617F). Acta Haematol. 2010;123(2):84-7 indexat ISI IF=1.069 73. Cucuianu A, Precup R. A hypothetical-mathematical model of acute myeloid leukaemia pathogenesis. Computational and Mathematical Methods in Medicine, 2010, 11 (1):49 65 indexat ISI IF=0 74. I. D. Postescu, P. Virág, M. Achim, E. Fischer-Fodor: Influence of palm oil on doxorubicine induced cytotoxicity in normal and tumor cell cultures, Phytoter. Res. 2010, 24, 154-156, i.f. 1.772. 75. L. I. Sabău, G. Damian, D. Daicoviciu, A. Mureăan, I. D. Postescu, D. Mihu, C. Mihu, N. Costin, C. Alb: In vivo study regarding antioxidant effect of red grape polyphenol extract using biochemical and FT-IR methods, J.Optoel.Adv.Mater. (JOAM), 2(1), 2010, 44-49, i.f. 0.577. 29
76. T. Dicu, I. D. Postescu, C. Tatomir, M. Tămaş, C. Cosma: A method to measure the antioxidant properties of polyphenolic compounds in trapping DPPH radical, under review at Ital.J.Food Sci, 2010, i.f. 0.462. 77. I. D. Postescu, P. Virág, T. Dicu, C. Tatomir, E. Fischer-Fodor, I. Brie, M. Perde- Schrepler, I. V. Cernea: The cyto- and radioprotective effects of a whey protein isolate, under review at Dairy Sci. Technol, 2010, i.f. 1.012. 78. C. Tomuleasa, O. Soriţãu, I. Brie, E. Páll, V. Foris, T. Dicu, P. Virag, A. Irimie, G. Kacsó: Mesenchymal stem cell irradiation in culture engages differential effect of hyperfractionated radiotherapy for head and neck cancers, Journal of Balkanic Union of Oncology, 15:348-356, 2010.Factor de Impact 0.783 79. C. Tomuleasa, O. Soriţău, D. Rus-Ciucă, T. Pop, D. Todea, O. Mosteanu, B. Pintea, V. Foris, S. Şuşman, G. Kacsó, A. Irimie: Isolation and Characterization of Hepatic Cancer Cells with Stem-like Properties from Hepatocellular Carcinoma, J Gastrointestinal Liver Dis, 19, 1, 2010, 61-67, i.f. 1.265. 80. O. Soritau, C. I. Tomuleasa, E. Pall, P. Virag, E. Fischer-Fodor, V. Foris, O. Barbos, C. Tatomir, G. Kacso, A. Irimie: Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer, Romanian Journal of Morphology and Embryology, 2010, 51 (2): 259-64. 81. C. Tomuleasa, G. Kacso, O. Soritau, S. Susman, A. Irimie, P. Virag: Cellular interactions in prostate cancer genesis and dissemination. Looking beyond the obvious, Romanian Journal of Morphology and Embryology, 2010, 51 (3): 3-6. 82. C.G. Precup, D. Gonganau-Nitu, R.R. Scurtu, G. Dindelegan, A. Biro, O. Soritau, C. Crişan, O. Serban, G. Pufu, C. Ciuce.: Assessement by laser Doppler of the peripheral 30
tumour perfusion after radiofrequency ablation for colorectal liver mestasisexperimental study. Chirurgia (Bucur). 2010 Jan-Feb;105(1):71-6. 83. O. Lucaciu, M. Băciuţ, G. Băciuţ, R. Câmpian, O. Soriţău, S. Bran, B. Crişan, L. Crişan.: Tissue engineered bone versus alloplastic commercial biomaterials in craniofacial reconstruction. Rom J Morphol Embryol. 2010;51(1):129-36. 84. S.Clichici, A.Filip, D. Daicoviciu, R.M. Ion, T. Mocan, C.Tatomir, L.Rogojan, D.Olteanu, A. Muresan: The dynamics of reactive oxygen speciesin photodynamic therapywith tetra sulfophenil- porphyrin. Acta Physiologica Hungarica, vol 97 (1), 43-55, 2010. ISSN 0231-424X (ISI), i.f. 0.491. 31
Citari ISI 1. Erlotinib in previously treated non-small-cell lung cancer nejm.org [HTML] Rodrigues Pereira, T Ciuleanu, EH Tan, V - England Journal of, 2005 - content.nejm.org. Results The median age of the 731 patients who underwent randomization was 61.4 years; 49 percent had received two prior chemotherapy regimens, and 93 percent had received platinum-based chemotherapy. The response rate was 8.9 percent in the erlotinib group... Citat de 2032 ori - Articole cu conţinut similar - Toate cele 17 versiuni 2. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, pharmacist.or.kr [PDF] P Parikh, J Rodrigues Pereira, T Ciuleanu, J von Pawel - The Lancet, 2005 - Elsevier 1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7 2 months, median survival did not differ significantly between the groups in the overall population (5 6 months for gefitinib and 5 1 months for placebo; hazard ratio 0 89 [95% CI 0 77 1 02], p=0 087) or... Citat de 941 ori - Articole cu conţinut similar - Toate cele 11 versiuni 3. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer\ascopubs.org [HTML], JR Pereira, T Ciuleanu, J von Pawel, C - Journal of Clinical, 2006 - jco.ascopubs.org Results High EGFR gene copy number was a predictor of a gefitinib-related effect on 32
survival (hazard ratio [HR], 0.61 for high copy number and HR, 1.16 for low copy number; comparison of high v low copy number HR, P =.045). EGFR protein expression was also related to... Citat de 315 ori - Articole cu conţinut similar - Toate cele 10 versiuni 4. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III, R Ramlau, N Ghilezan, T Ciuleanu, B Cucevic, K - Lung Cancer, 2006 - Elsevier Between November 1999 and November 2002, we enrolled 352 patients (median age: 57 years; stage IV disease: 74%; Karnofsky performance status (KPS) >80: 41%). Following initial therapy, 206 patients were randomized and treated with gemcitabine (138) or best... Citat de 72 ori - Articole cu conţinut similar - Toate cele 4 versiuni 5. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer ascopubs.org [HTML]MER O'Brien, TE Ciuleanu, H Tsekov, Y - Journal of Clinical, 2006 - jco.ascopubs.org RESULTS: In the intent-to-treat population, survival (primary end point) was prolonged in the topotecan group (log-rank P =.0104). Median survival with BSC was 13.9 weeks (95% CI, 11.1 to 18.6) and with topotecan, 25.9 weeks (95% CI,18.3 to 31.6). Statistical significance for... Citat de 84 ori - Articole cu conţinut similar - Toate cele 9 versiuni 6. D Cosaceanu, RA Budiu, M Carapancea, J Castro, R - Oncogene, 2006 - nature.com Ionizing radiation exposure results in the activation of several tyrosine kinase receptors that participate in radiation-induced DNA damage response and radioresistance. We 33
previously showed that insulin-like growth factor 1 receptor (IGF-1R) inhibition enhanced radiosensitivity of non-... Cited by 21 - Related articles - BL Direct - All 5 versions 7. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, ascopubs.org [PDF] Pinter, M Smakal, TE Ciuleanu, L Chen, T - Journal of Clinical, 2008 - jco.ascopubs.orgrobert E. Smith Jr, Matti S. Aapro, Heinz Ludwig, Tamás Pintér, Martin Šmakal, Tudor E. Ciuleanu, Li Chen, Tom Lillie, and John A. Glaspy From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los... Citat de 68 ori - Articole cu conţinut similar - Toate cele 8 versiuni 8. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 oncobaleares.es [PDF] T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M - The Lancet, 2009 - ElsevierThis randomised double-blind study was undertaken in 83 centres in 20 countries. 663 patients with stage IIIB or IV disease who had not progressed on four cycles of platinumbased chemotherapy were randomly assigned (2:1 ratio) to receive pemetrexed (500 mg/m 2, day 1) plus best... Citat de 68 ori - Articole cu conţinut similar - Toate cele 14 versiuni 9. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 34
oncobaleares.es [PDF]T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M - The Lancet, 2009 - Elsevier This randomised double-blind study was undertaken in 83 centres in 20 countries. 663 patients with stage IIIB or IV disease who had not progressed on four cycles of platinum-based chemotherapy were randomly assigned (2:1 ratio) to receive pemetrexed (500 mg/m 2, day 1) plus best... Cited by 62 - Related articles - All 14 versions 10. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after maastro.nl [PDF], E Quoix, C Faivre-Finn, T Ciuleanu, R Arriagada, R - Lancet Oncol, 2009 - maastro.nlstandard-dose versus higher-dose prophylactic cranial... RTOG 0212, and IFCT 99-01): a randomised clinical trial... Cécile Le Péchoux, Ariane Dunant, Suresh Senan, Aaron Wolfson, Elisabeth Quoix, Corinne Faivre-Finn, Tudor Ciuleanu, Rodrigo Arriagada, Richard Jones, Rinus... Citat de 12 ori - Articole cu conţinut similar - Afişare ca HTML - Toate cele 13 versiuni 12. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy F Cappuzzo, T Ciuleanu, L Stelmakh, S - ASCO Meeting, 2009 - meeting.ascopubs.org Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival versus placebo (P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study (BO18192) was initiated to evaluate E as maintenance therapy after standard 1st-line platinum-based... Cited by 53 - Related articles 11. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer AM Vlad, RA Budiu, DE Lenzner, Y Wang, JA - 35